The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - AstraZeneca
 
Research Funding - AstraZeneca (Inst)

Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genentech; Merck; Pfizer; QED Therapeutics; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Genentech
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst)
 
François Laliberté
Research Funding - AstraZeneca (Inst)
 
Yunes Doleh
No Relationships to Disclose
 
Cristi O'Connor
Research Funding - AstraZeneca (Inst)
 
Mei Sheng Duh
No Relationships to Disclose
 
Rahul Shenolikar
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca